Iron overload is frequently observed before hematopoietic SCT (HSCT), due to multiple RBC transfusions, and is considered a significant contributor to treatment-related mortality. 1 Little is known of the effects of iron overload on hematopoietic recovery after transplant. In fact, several patients present impaired recovery of hemopoiesis after transplant, with transfusion dependence and/or neutropenia and thrombocytopenia. All the same, the possible effect of iron chelators on the restoration of normal hemopoiesis after transplant is still unknown.
Here we report on eight patients with incomplete hematological reconstitution after allogeneic HSCT, heavily transfused before transplant, who were treated after HSCT with deferasirox (Table 1) . Patients were selected according to the following inclusion criteria: (1) recipient of allogeneic HSCT; (2) transfused pre-transplant with more than 20 RBC units; (3) incomplete hematological recovery; (4) transfusion dependence; (5) serum ferritin X1800 ng/mL; (6) normal creatinine value; (7) signed informed consent. Before starting deferasirox, all patients were fully engrafted and in CR. All patients received an initial dose of deferasirox 10 mg/kg/day, later adjusted according to side effects. Deferasirox was well tolerated; all patients experienced an increase in Hb levels, with a reduction in the frequency of RBC transfusions, followed by transfusion independence (median time: 23 days from the first dose of deferasirox; Figure 1a ). In addition, it was promptly (median time: 26 days) associated with hematological improvement, with sustained values and no further platelet support or growth factor administration. Moreover, ferritin values were progressively reduced with deferasirox treatment (Figure 1b) . The workup for other etiologies was negative; no concomitant infection was documented (CMV: negative; HHV-6: negative; EBV: negative). No relevant modifications with immunosuppressive or myelosuppressive drugs were made during deferasirox treatment. In our opinion, deferasirox had a direct stimulatory effect on hematopoiesis after allo-SCT.
The role of iron overload after HSCT is not completely understood. Recent evidence suggests that increased liver iron concentration (LIC) measured with liver magnetic resonance (R2-magnetic resonance imaging) or liver biopsy do not correlate with survival or incidence of complications at 1-year post transplant. 2, 3 However, in the recent past, an association between serum ferritin values before HSCT (used as a surrogate measure of iron overload) and an adverse outcome was shown, 1 leading to the conclusion that hyperferritinemia has a detrimental effect on survival up to 5-year post transplant. Thus, interventions to reduce excessive body iron might be beneficial both before and after HSCT. In the peri-transplant period, BM suppression caused by chemotherapeutics substantially increases toxic nontransferrinbound iron levels, because erythropoiesis is the main route of circulating iron utilization. An attractive explanation for the post 
www.nature.com/bmt transplantation iron overload in patients affected with GVHD is the deregulation of hepcidin production. 4 Notwithstanding these pros and cons, no reports have up to now focused on the possible effect of iron chelators after transplant on the restoration of normal hemopoiesis and, in particular, of transfusion independence. Out of the transplant field, this effect is well known in thalassemia, as well as in heavily transfused MDS. In addition, a beneficial effect was reported in patients affected by aplastic anemia with iron overload due to transfusions. This prompted us to use deferasirox in patients transplanted for hematological malignancies, heavily transfused before transplant, persistently anemic and transfusion dependent after transplant. The mechanisms underlying how deferasirox could induce hematologic improvement have yet to be elucidated. Reduction in oxidative stress, a state that has a variety of inhibitory effects on erythroid and hematopoietic function, 5 has been proposed. This hypothesis is supported by the ability of deferasirox to provide 24-h sustained suppression of labile plasma iron and to significantly reduce reactive oxygen species. 6 In vitro and in vivo data have demonstrated the inhibitory effects of deferasirox on Nuclear factor-kappa B activity. Alternative mechanisms may include redistribution of iron from storage sites to hematopoietic tissue, or an effect on the clone or on BM. There is an increasing evidence from animal studies that iron overload affects erythropoietic capacity and leads to improvements in Hb levels and red cell survival, 7 probably influencing the microenvironment. 8 In fact, trilineage restoration of hematopoiesis implies that the effect of iron chelation therapy is not restricted to the erythropoietic lineage, but may be exerted on the hematopoietic stem cells. Recent studies suggest that iron overload levels may contribute to cytopenias by damaging hematopoietic cells. Iron overload enhances the level of intracellular reactive oxygen species and promotes apoptosis of immature erythroblasts via suppression of the BCL2 expression. In addition, the reduction in reactive oxygen species by iron chelation can inhibit apoptosis. 9 Forni et al. 10 demonstrated that deferasirox induces a higher BFU-E score in thalassemia major, with two possible explanations: (a) induction of a higher number of BFU-E moving from the BM to peripheral blood; or, (b) deferasirox may render erythropoiesis more efficient and, as a consequence, more BFU-E may produce a discrete burst with a higher production. This observation should stimulate further research into the possible role of the deferasirox therapy in improving erythropoiesis after transplant for acute leukemia or aplastic anemia.
However, it cannot be excluded that the improvement might be due to the reduction of iron overload. A relatively rapid hematologic response to deferasirox suggests that such a response might be more drug specific. In this regard, there is the possibility that the deferasirox effect could be due to an intracellular iron chelation per se, similar to other chelators, or could be related to a specific ability of the drug to sequester iron in a particular target not accessible to deferoxamine or deferiprone. 10 In conclusion, our experience indicates that oral deferasirox might have a beneficial effect on the hematopoietic recovery in patients submitted to allo-SCT, heavily transfused before transplant. Further studies, conducted in larger patient populations with highly specific and more accurate measurements of iron overload, such as R2-magnetic resonance imaging or liver biopsy, are warranted to define if the principal effector is the (partial) correction of iron overload (and/or of hyperferritinemia), or a direct stimulatory effect of deferasirox on post transplant hematopoiesis. 
